2010『蛋白質工程及抗體藥物治療』研討會(2010/12/23)

December 6th, 2010 | Categories: 2010 | Tags:

財團法人生物技術開發中心 『蛋白質工程及抗體藥物治療』研討會

根據IMS的統計,全球生技藥品市場2009年3月年度累計(moving annual total, MAT)達1,200億美元,占全球藥品市場的17%。2005年3月~2009年3月間,全球生技藥品市場的年複合成長率(compound annual growth rate, CAGR)為12.5%,高於同期全球藥品市場的7.9%;其中根據Med Ad News針對全球銷售額前百大藥品的統計,2009年全球銷售額前十大藥品中,有五項屬於生技藥品,其中單株抗體藥物Remicade(Infliximab)則是全球最暢銷的生技藥品,而在未來治療性抗體藥物仍將是許多公司的開發主流,預計至2010年市場值將達260億美元年複成長率18%。(資料來源:生物技術開發中心ITIS 計畫)

有鑑於此生技中心特別邀請了Dr. Herren Wu (Vice President, MedImmune, USA )、Dr. Zhenping Zhu (Executive Vice President, Global Biologics R&D / President & CEO, Kadmon China )及Dr. Larry Lo(Senior Scientist II, Human Genome Sciences, USA)三位提供在蛋白質工程及抗體藥物治療研發過程中之寶貴經驗,並敬邀台灣業界先進一同與會進行交流。

主辦單位:財團法人生物技術開發中心
會議時間:99年12月23日 下午 13:00-17:00
地  點:台北縣汐止市康寧街169巷101號 財團法人生物技術開發中心
B棟1樓 國際會議廳

報名方式:即日起開始報名,免報名費,額滿為止,報名請填妥報名表後
以電子郵件或傳真回覆,回函逕請於12月15日前E-mail至
alice_lu@dcb.org.tw;或傳真至(02)2694-5648,謝謝!

下載報名表(DOC)

◇ 煩請填寫清楚,日後相關訊息,本中心將以email寄發提供您參考,謝謝!
◇ 若有任何問題請洽以下專線,謝謝!
洽詢專線:(02)2695-6933轉2432 呂韋箴小姐

會議議程:
.

Time Agenda Venue
13:00-13:05

(5 min.)

Introduction 生技中心 B棟1樓國際會議廳
13:05-13:50
(45 min.)
TopicNext-generation biologics: non-traditional IgG and non-IgG biologics

講者:Dr. Herren Wu

13:50-14:35
(45 min.)
TopicAntibody developability assessment and next generation antibodies

講者:Dr. Zhenping Zhu

14:35-15:05
(30 min.)
Break
15:05-15:50
(45 min.)
TopicBelimumab: A Human Monoclonal Antibody Against BLyS for  the Treatment of SLE

講者:Dr. Larry Lo

15:50-17:00
(70 min.)
Q&A / Panel Discussion

講  者:
Dr. Herren Wu: Vice President, R&D, Global Head of Technology and Lead Generation, and Head of Antibody Discovery and Protein Engineering, MedImmune, USA

Dr. Zhenping Zhu:Executive Vice President, Global Biologics R&D, President & CEO, Kadmon China

Dr. Larry Lo:  Senior Scientist II, Human Genome Sciences, USA

講者介紹:

Herren Wu

Dr. Herren Wu is vice president of R&D, head, of antibody discovery and protein engineering and global head of technology in MedImmune. In this position, he is responsible for antibody discovery, antibody/protein engineering, production cell line generation, structural biology, protein mimetics and new technology. He leads an organization of about 80 scientists. He is actively involved in developing MedImmune’s clinical- and preclinical-stage product candidates, and also participates in target discovery and validation for early research projects. He plays an essential role in discovering and developing an anti-RSV mAb, motavizumab that is currently under FDA review for market approval.
Dr. Wu has more than 20-year experience in antibody discovery and protein engineering. He started as director, protein engineering and structure in MedImmune in 2002. Prior to joining MedImmune, he served as head, molecular biology department at Tanox, Inc. (acquired by Genentech in 2007). Before joining Tanox, he held a variety of research positions up to associate director, antibody engineering and discovery at Applied Molecular Evolution (now a subsidiary of Eli Lilly & Co.). Dr. Wu was included in the International Who’s Who of Professionals, 2003-2004 edition, as well as the Who’s Who in Science and Engineering, 2000-2001 edition. He is the recipient of the Senior Technology Fellow Emerald Honors award presented at the 2006 Minorities in Research Science Conference. He is also named as co-inventor on 9 issued patents and 35 patent applications related to antibody technology and antibody/protein therapy.

Dr. Wu received his bachelor’s degree in chemistry from the National Taiwan University and his doctorate in molecular and cellular biology from the University of Massachusetts, Amherst. He completed his postdoctoral training at The Scripps Research Institute in La Jolla, California.

Zhenping Zhu
Dr. Zhenping Zhu is currently Executive Vice President, Global Biologics R&D, Kadmon Pharmaceuticals LLC, New York, and President and CEO of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis Biologics from February 2009 to July 2010. At Novartis, Dr. Zhu established and managed biologics research groups globally in Basel (Switzerland), Cambridge (US), and Shanghai (China), and was responsible for the discovery, design and selection of novel biologic drugs, including monoclonal antibodies, recombinant proteins and engineered molecules that address diseases of high unmet need. From 1996 to 2009, Dr. Zhu was Vice President of Antibody Technology and Immunology at ImClone Systems, which was acquired by Eli Lilly in late 2008, and has led research teams that successfully discovered and engineered several novel antibodies that are currently in phase I to III clinical development for various oncology indications. Dr. Zhu has been working in the area of antibody technologies and biotherapeutics for over 25 years, and has published over 180 peer-reviewed scientific papers, including original research articles, invited reviews and book chapters. Dr. Zhu is also a frequently invited speaker at various international conferences/symposiums in life sciences. Dr. Zhu earned his medical degree from Jiangxi Medical College and his MSc in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College. He received his PhD in Immunology and Pathology from Dalhousie University, and performed his postdoctoral work in antibody/protein
engineering at Genentech Inc. Dr. Zhu is a member of the BayHelix Group, an organization of leaders of Chinese heritage in the global life sciences and healthcare community.

Larry Lo

Dr. Larry Lo currently is a Senior Scientist II in Clinical Immunology at Human Genome Sciences (HGS). He started in Antibody Development department at HGS where he developed therapeutic antibodies against human chemokine and chemokine receptor using phage display system. In the past 7 years, the major roles of his group were to develop PK, immunogenicity and neutralization assays and analyze the samples to support HGS pre-clinical and clinical study (Phase I to Phase III) for human therapeutic antibodies. Dr. Lo is current a leading scientist to develop new therapeutic antibody pipelines against new targets, including oncology and autoimmune disease. He is also a critical member to evaluate novel antibody technology platform and potential in-license opportunity at HGS. Dr. Lo was also one of core team members for FDA advisory committee review meeting for raxibacumab (2009) and belimumab (2010). Prior to HGS, Dr. Lo worked as a Scientist at MedImmune where he developed human/humanized catalytic antibody for cocaine adduct therapeutic. Dr. Lo obtained his Ph.D. in Macromolecular, Cellular Structure and Chemistry from The Scripps Research Institute. Following his Ph.D., Dr. Lo continued his work at Scripps in capacity of Research Scientist and then Assistant Professor in Chemistry Department. During his career at Scripps, his works focused in to develop human antibody for catalysis and cancer therapeutic from human antibody phage libraries.

|

Referrer Plugin made by Electric Guitars.